Abstract
Use of a rare disease patient registry in long-term post-authorisation drug studies: a model for collaboration with industry
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have